Professor Steven Gill pioneered the original work using Glial cell line-Derived Neurotrophic Factor (GDNF) in people with Parkinson’s. Since the initial pilot study, he has designed a new delivery system to enable this key growth factor to be delivered optimally, not only in terms of safety and efficacy, but also in a way which can be administered to patients practically and accurately.

Professor Gill’s Functional Neurosurgery Research Group has extensive pre-clinical and clinical Convection-enhanced delivery (CED) research experience and has successfully completed a number of studies which have led directly to clinical trials. This group has unique and world-leading CED catheter technology which is currently being used to treat patients with a range of neurological disorders including adults and children with malignant brain tumours and Parkinson’s Disease.